Set up in 2010, it addresses an area of drug development that has been neglected for several decades: lipids.

The company’s portfolio consists of three compounds currently under development: the oral and topical DS107 for atopic dermatitis, pruritus and other dermatological disorders, oral DS102 for anti-fibrosis, and oral and topical DS109 for diabetic neuropathy and acne and psoriasis. The company plans to add more bioactive lipids into the current portfolio in years to come.